Company intelligence / Profile preview

DiObex, Inc.

San Francisco, California, United Statesbiospace.com ↗

Ownership: Private
Development stage: Phase 2

Overview

DiObex had two lead drug candidates in mid-stage clinical development. DIO-901 (very low dose glucagon) was being developed for preventing insulin-induced hypoglycemia in diabetes patients and had received Fast Track status from the FDA. DIO-902 (levdexketoconazole), a cortisol synthesis inhibitor, was in development for type 2 diabetes and diabetic nephropathy. The company completed Phase 2a clinical trials and was planning to initiate a 16-week Phase 2b dose-ranging study in patients with type 2 diabetes by mid-2007.[1][4]

Therapeutic areas: EndocrinologyMetabolic DisordersNephrology
Modalities: Small moleculespeptides
Industry: Biotech

Drug pipeline

1 asset

DIO-902

Discontinued

Beyond the preview

Go deeper on DiObex, Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on DiObex, Inc..

Explore the full profile